211 related articles for article (PubMed ID: 31792072)
21. Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53.
Scarpetti L; Oturkar CC; Juric D; Shellock M; Malvarosa G; Post K; Isakoff S; Wang N; Nahed B; Oh K; Das GM; Bardia A
Oncologist; 2023 Apr; 28(4):358-363. PubMed ID: 36772966
[TBL] [Abstract][Full Text] [Related]
22. Post-transcriptional regulation of human breast cancer cell proteome by unliganded estrogen receptor β via microRNAs.
Nassa G; Tarallo R; Giurato G; De Filippo MR; Ravo M; Rizzo F; Stellato C; Ambrosino C; Baumann M; Lietzèn N; Nyman TA; Weisz A
Mol Cell Proteomics; 2014 Apr; 13(4):1076-90. PubMed ID: 24525454
[TBL] [Abstract][Full Text] [Related]
23. Quantitative mapping of RNA-mediated nuclear estrogen receptor β interactome in human breast cancer cells.
Giurato G; Nassa G; Salvati A; Alexandrova E; Rizzo F; Nyman TA; Weisz A; Tarallo R
Sci Data; 2018 Mar; 5():180031. PubMed ID: 29509190
[TBL] [Abstract][Full Text] [Related]
24. ΕGFR/ERβ-Mediated Cell Morphology and Invasion Capacity Are Associated with Matrix Culture Substrates in Breast Cancer.
Kyriakopoulou K; Riti E; Piperigkou Z; Koutroumanou Sarri K; Bassiony H; Franchi M; Karamanos NK
Cells; 2020 Oct; 9(10):. PubMed ID: 33050027
[TBL] [Abstract][Full Text] [Related]
25. Estrogen receptor-beta is a potential target for triple negative breast cancer treatment.
Austin D; Hamilton N; Elshimali Y; Pietras R; Wu Y; Vadgama J
Oncotarget; 2018 Sep; 9(74):33912-33930. PubMed ID: 30338035
[TBL] [Abstract][Full Text] [Related]
26. The orphan nuclear receptor estrogen-related receptor beta (ERRβ) in triple-negative breast cancer.
Fernandez AI; Geng X; Chaldekas K; Harris B; Duttargi A; Berry VL; Berry DL; Mahajan A; Cavalli LR; Győrffy B; Tan M; Riggins RB
Breast Cancer Res Treat; 2020 Feb; 179(3):585-604. PubMed ID: 31741180
[TBL] [Abstract][Full Text] [Related]
27. Androgen and Estrogen β Receptor Expression Enhances Efficacy of Antihormonal Treatments in Triple-Negative Breast Cancer Cell Lines.
Crespo B; Illera JC; Silvan G; Lopez-Plaza P; Herrera de la Muela M; de la Puente Yagüe M; Diaz Del Arco C; Illera MJ; Caceres S
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338747
[TBL] [Abstract][Full Text] [Related]
28. Genomic regulation of invasion by STAT3 in triple negative breast cancer.
McDaniel JM; Varley KE; Gertz J; Savic DS; Roberts BS; Bailey SK; Shevde LA; Ramaker RC; Lasseigne BN; Kirby MK; Newberry KM; Partridge EC; Jones AL; Boone B; Levy SE; Oliver PG; Sexton KC; Grizzle WE; Forero A; Buchsbaum DJ; Cooper SJ; Myers RM
Oncotarget; 2017 Jan; 8(5):8226-8238. PubMed ID: 28030809
[TBL] [Abstract][Full Text] [Related]
29. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
[TBL] [Abstract][Full Text] [Related]
30. Genome-wide mapping of estrogen receptor-beta-binding regions reveals extensive cross-talk with transcription factor activator protein-1.
Zhao C; Gao H; Liu Y; Papoutsi Z; Jaffrey S; Gustafsson JA; Dahlman-Wright K
Cancer Res; 2010 Jun; 70(12):5174-83. PubMed ID: 20501845
[TBL] [Abstract][Full Text] [Related]
31. ERβ decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function.
Bado I; Nikolos F; Rajapaksa G; Gustafsson JÅ; Thomas C
Oncotarget; 2016 Mar; 7(12):13599-611. PubMed ID: 26871946
[TBL] [Abstract][Full Text] [Related]
32. Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer.
Quintero M; Adamoski D; Reis LMD; Ascenção CFR; Oliveira KRS; Gonçalves KA; Dias MM; Carazzolle MF; Dias SMG
BMC Cancer; 2017 Nov; 17(1):727. PubMed ID: 29115931
[TBL] [Abstract][Full Text] [Related]
33. Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study.
Wisinski KB; Xu W; Tevaarwerk AJ; Saha S; Kim K; Traynor A; Dietrich L; Hegeman R; Patel D; Blank J; Harter J; Burkard ME
Clin Breast Cancer; 2016 Aug; 16(4):256-61. PubMed ID: 27133732
[TBL] [Abstract][Full Text] [Related]
34. Quantitative proteomics and transcriptomics addressing the estrogen receptor subtype-mediated effects in T47D breast cancer cells exposed to the phytoestrogen genistein.
Sotoca AM; Gelpke MD; Boeren S; Ström A; Gustafsson JÅ; Murk AJ; Rietjens IM; Vervoort J
Mol Cell Proteomics; 2011 Jan; 10(1):M110.002170. PubMed ID: 20884965
[TBL] [Abstract][Full Text] [Related]
35. ERα and ERβ Homodimers in the Same Cellular Context Regulate Distinct Transcriptomes and Functions.
Song D; He H; Indukuri R; Huang Z; Stepanauskaite L; Sinha I; Haldosén LA; Zhao C; Williams C
Front Endocrinol (Lausanne); 2022; 13():930227. PubMed ID: 35872983
[TBL] [Abstract][Full Text] [Related]
36. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.
Mishra AK; Abrahamsson A; Dabrosin C
Oncotarget; 2016 Aug; 7(35):56876-56888. PubMed ID: 27486755
[TBL] [Abstract][Full Text] [Related]
37. Biologic roles of estrogen receptor-β and insulin-like growth factor-2 in triple-negative breast cancer.
Hamilton N; Márquez-Garbán D; Mah V; Fernando G; Elshimali Y; Garbán H; Elashoff D; Vadgama J; Goodglick L; Pietras R
Biomed Res Int; 2015; 2015():925703. PubMed ID: 25874233
[TBL] [Abstract][Full Text] [Related]
38. BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer.
De Santis F; Romero-Cordoba SL; Castagnoli L; Volpari T; Faraci S; Fucà G; Tagliabue E; De Braud F; Pupa SM; Di Nicola M
Cell Oncol (Dordr); 2022 Apr; 45(2):257-274. PubMed ID: 35357654
[TBL] [Abstract][Full Text] [Related]
39. Estrogen Receptors alpha and beta as determinants of gene expression: influence of ligand, dose, and chromatin binding.
Chang EC; Charn TH; Park SH; Helferich WG; Komm B; Katzenellenbogen JA; Katzenellenbogen BS
Mol Endocrinol; 2008 May; 22(5):1032-43. PubMed ID: 18258689
[TBL] [Abstract][Full Text] [Related]
40. Regulation of IMP3 by EGFR signaling and repression by ERβ: implications for triple-negative breast cancer.
Samanta S; Sharma VM; Khan A; Mercurio AM
Oncogene; 2012 Nov; 31(44):4689-97. PubMed ID: 22266872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
